Drugs / Immunomodulatory DC vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03914768 | May 2026 → May 2029 expected | malignant glioma | Shenzhen Geno-Immune Medical Institute | Enrolling by invitation | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Immunomodulatory DC vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03914768 ↗ |
| Known as | DC vaccine | “This study will inject DC vaccine cells near lymphoid tissue close to the tumor.” NCT03914768 ↗ |
| Modality | Vaccine | “The treatment uses immunomodulatory vaccine generated by autologous dendritic cells (DCs) pulsed with genetically modified tumor cells or tumor-related antigens including...” NCT03914768 ↗ |
| Route | Other | “This study will inject DC vaccine cells near lymphoid tissue close to the tumor.” NCT03914768 ↗ |